Abstract 3752
Background
The expanding armamentarium of wearable devices offers new opportunities to supplement physician-assessed performance status (PS) with continuously acquired real-life patient data. It is relevant to identify and characterize the level of association between wearable device physical activity (PA) metrics and PS in cancer patients as a first step into evaluating their potential combined utility in evaluating treatment outcomes and clinical decisions. Therefore, we conducted a systematic review to examine the association between wearable device PA metrics and PS in cancer patients.
Methods
We searched PubMed and EMBASE for studies that were conducted among adults with cancer, quantitatively assessed a relation between wearable device PA metrics and PS, and had a full text available in English. We extracted information on study design and population, wearable device type and PA metrics, outcome definitions, and results. Included studies were subjected to methodological quality assessment.
Results
Nine studies with a total of 574 patients were included in this review. Eight studies had a prospective observational study design and all studies reported on a different combination of wearable device PA metrics including: steps per day (n = 5), sedentary behavior (n = 5), and PA volume/intensity (n = 4). Much heterogeneity was observed regarding study population, wearable devices used, and reporting of results. None of the studies could be defined to be of ‘high methodological quality’ (≥ 70%): mean methodological quality was 47% and ranged from 40-60%. We found moderate evidence for a positive association between steps per day and PS, and for a negative association between sedentary behavior and PS.
Conclusions
Much heterogeneity was identified between studies with regards to study population, reported PA metrics, and used devices. Nevertheless, results of this study indicate that higher daily step count is associated with better PS in cancer patients. Whereas sedentary behavior is associated with worse PS. The next step into determining their potential combined utility in evaluating treatment outcomes and clinical decisions is to investigate the association between wearable device PA metrics and cancer outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
H.W. Wilmink: Advisory / Consultancy: Shire; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Servier; Research grant / Funding (institution): Halozyme; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Merck. H.W.M. van Laarhoven: Research grant / Funding (institution): Roche; Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): MSD; Advisory / Consultancy, Research grant / Funding (institution): Nordic; Research grant / Funding (institution): Philips. M. van Oijen: Research grant / Funding (institution): Roche; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Servier; Research grant / Funding (institution): Nordic; Research grant / Funding (institution): Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
3186 - The landscape of immuno-oncology clinical trials in China
Presenter: Dawei Wu
Session: Poster Display session 3
Resources:
Abstract
3468 - Clinical Significance of Immune-related Creatine Phosphokinase Increase Associated with Anti PD1/PD-L1 immunotherapies.
Presenter: Samia Hajem
Session: Poster Display session 3
Resources:
Abstract
3836 - Thyroid toxicity and anti-thyroid antibodies as predictive markers for patients treated with anti-PD1 checkpoint therapy
Presenter: Wim Meer
Session: Poster Display session 3
Resources:
Abstract
1343 - Treatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors
Presenter: Thura Win Htut
Session: Poster Display session 3
Resources:
Abstract
5783 - Immune-related adverse events (irAEs) with single-agent PD-1 vs PD-L1 inhibitors: a meta-analysis of 8,730 patients from clinical trials
Presenter: Guru Sonpavde
Session: Poster Display session 3
Resources:
Abstract
5422 - EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy
Presenter: Marie Kostine
Session: Poster Display session 3
Resources:
Abstract
1202 - Radiographic characteristics and poor prognostic factors of interstitial lung disease (ILD) in nivolumab-treated patients with non-small cell lung cancer (NSCLC)
Presenter: Shinichi Sasaki
Session: Poster Display session 3
Resources:
Abstract
2749 - Use of Checkpoint Inhibitors (CPI) in Allogeneic Stem Cell Transplant Recipients: An Institutional Experience and A Systemic Review of the Literature
Presenter: Chantal Saberian
Session: Poster Display session 3
Resources:
Abstract
3256 - Deep Learning Radiomics distinguishes intrapulmonary Disease from Metastases in Immunotherapy-treated Melanoma Patients
Presenter: Thi Dan Linh Nguyen-Kim
Session: Poster Display session 3
Resources:
Abstract
5031 - Sarcoidosis-Like Reaction Mimics Progression in patients treated with immune checkpoint inhibitors
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract